Info: Read More
  • 中药标准品生产商,产品定制服务
  • 人参皂苷Rd

    Ginsenoside Rd

    人参皂苷Rd
    产品编号 CFN99975
    CAS编号 52705-93-8
    分子式 = 分子量 C48H82O18 = 947.2
    产品纯度 >=98%
    物理属性 Powder
    化合物类型 Triterpenoids
    植物来源 The roots of Panax ginseng C. A. Mey.
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    人参皂苷Rd CFN99975 52705-93-8 10mg QQ客服:2056216494
    人参皂苷Rd CFN99975 52705-93-8 20mg QQ客服:2056216494
    人参皂苷Rd CFN99975 52705-93-8 50mg QQ客服:2056216494
    人参皂苷Rd CFN99975 52705-93-8 100mg QQ客服:2056216494
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • Universidade Federal de Santa Catarina (Brazil)
  • Universiti Kebangsaan Malaysia (Malaysia)
  • University of Minnesota (USA)
  • Utrecht University (Netherlands)
  • University of South Australia (Australia)
  • Florida International University (USA)
  • Celltrion Chemical Research Institute (Korea)
  • University of Hawaii Cancer Center (USA)
  • University of Toulouse (France)
  • Universidade Federal de Goias (UFG) (Brazil)
  • University of Canterbury (New Zealand)
  • Kyushu University (Japan)
  • Harvard University (USA)
  • Lodz University of Technology (Poland)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Phytomedicine.2021, 83:153483.
  • J Biomol Struct Dyn.2022, 1-21.
  • Preprints2022, 202211.0388.v1.
  • J Agric Food Chem.2016, 64(35):6783-90
  • Phytomedicine.2023, 117:154929.
  • Pharmaceuticals (Basel).2021, 14(7):633.
  • ScientificWorldJournal.2022, 2022:4806889.
  • Inflammation.2015, 38(4):1502-16
  • Molecules.2020, 25(9):2081.
  • Sci Rep.2021, 11(1):21038.
  • Heliyon.2022, 8(12):e12031.
  • J Agric Food Chem.2019, 67(27):7748-7754
  • Front Immunol.2020, 11:598556.
  • Molecules.2019, 24(24),4583
  • Korean Herb. Med. Inf.2020, 8(2):233-242.
  • Front Pharmacol.2021, 12:744624.
  • BMC Complement Altern Med.2014, 14:242
  • J Int Med Res.2021, 49(7):3000605211032849.
  • Life Sci.2023, 317:121458.
  • bioRxiv-Pharm.&Toxi.2022, 2022.481203.
  • Food Chem.2017, 221:1135-1144
  • J Nat Prod.2021, 84(9):2544-2553.
  • Oncotarget.2016, 8(51):88386-88400
  • ...
  • 生物活性
    Description: Ginsenoside Rd, a minor ginseng saponin, has several pharmacological activities such as immunosuppressive activity, anti-inflammatory activity, immunological adjuvant, anti-cancer activity and wound-healing activity. Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC50 of 12.05±0.82 μM in HepG2 cells. Rd inhibits expression of COX-2 and iNOS mRNA. Rd also inhibits Ca2+ influx. Rd inhibits CYP2D6, CYP1A2, CYP3A4, and CYP2C9, with IC50s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.
    Targets: VEGFR | Akt | ERK | PI3K | Calcium Channel | IL Receptor | IFN-γ | COX | NOS | CYP2D6 | CYP1A2 | CYP3A4 | CYP2C9
    In vitro:
    J Ethnopharmacol. 2012 Aug 1;142(3):754-61.
    Promotive effect of ginsenoside Rd on proliferation of neural stem cells in vivo and in vitro.[Pubmed: 22683911 ]
    Ginseng, the root of Panax ginseng C. A. MEYER (Araliaceae), is reputedly known for its nootropic and anti-aging functions and has been widely used to treat various diseases and enhance health for thousands of years in Asia. Recent studies revealed that ginsenoside, responsible for the pharmacological effects of ginseng, can prevent memory loss and improve spatial learning in mice, but underlying mechanisms are still largely unknown. Active neurogenesis in adult hippocampus is closely related to animals' learning and memory ability. The present study aimed to investigate the possible effects of ginsenoside Rd, one of the most effective ingredients in ginseng, on neurogenesis in vivo and in vitro.
    METHODS AND RESULTS:
    Adult rats and cultured neural stem cells were treated with ginsenoside Rd at different doses, and the changes in the proliferation and differentiation of neural stem cells were examined by immunohistochemistry and immunocytochemistry. Ginsenoside Rd significantly increased the numbers of BrdU(+) and DCX(+) cells in the hippocampal dentate gyrus but did not affect the ratio of NeuN/BrdU double-labeled cells to the total number of BrdU(+) cells. For cultured neural stem cells, ginsenoside Rd promoted the size and number of neurospheres, increased the number of BrdU(+) and Ki67(+) cells but did not affect the differentiation of neural stem cells into neurons, astrocytes and oligodendrocytes.
    CONCLUSIONS:
    These results indicate that ginsenoside Rd can enhance the proliferation but not affect the differentiation of neural stem cells in vivo and in vitro.
    Sci Rep . 2017 Oct 2;7(1):12552.
    Ginsenosides Rb3 and Rd reduce polyps formation while reinstate the dysbiotic gut microbiota and the intestinal microenvironment in Apc Min/+ mice[Pubmed: 28970547]
    Studies showed that manipulation of gut microbiota (GM) composition through the treatment of prebiotics could be a novel preventive measure against colorectal cancer (CRC) development. In this study, for the first time, we assessed the non-toxic doses of the triterpene saponins (ginsenoside-Rb3 and ginsenoside-Rd) - as prebiotics - that effectively reinstated the dysbiotic-gut microbial composition and intestinal microenvironment in an ApcMin/+ mice model. Rb3 and Rd effectively reduced the size and the number of the polyps that accompanied with the downregulation of oncogenic signaling molecules (iNOS, STAT3/pSTAT3, Src/pSrc). Both the compounds improved the gut epithelium by promoting goblet and Paneth cells population and reinstating the E-cadherin and N-Cadherin expression. Mucosal immunity remodeled with increased in anti-inflammatory cytokines and reduced in pro-inflammatory cytokines in treated mice. All these changes were correlating with the promoted growth of beneficial bacteria such as Bifidobacterium spp., Lactobacillus spp., Bacteroides acidifaciens, and Bacteroides xylanisolvens. Whereas, the abundance of cancer cachexia associated bacteria, such as Dysgonomonas spp. and Helicobacter spp., was profoundly lower in Rb3/Rd-treated mice. In conclusion, ginsenosides Rb3 and Rd exerted anti-cancer effects by holistically reinstating mucosal architecture, improving mucosal immunity, promoting beneficial bacteria, and down-regulating cancer-cachexia associated bacteria.
    In vivo:
    Acta Pharmacol Sin. 2015 Apr;36(4):421-8.
    Ginsenoside Rd promotes neurogenesis in rat brain after transient focal cerebral ischemia via activation of PI3K/Akt pathway.[Pubmed: 25832422]
    To investigate the effects of ginsenoside Rd (Rd) on neurogenesis in rat brain after ischemia/reperfusion injury (IRI).
    METHODS AND RESULTS:
    Male SD rats were subjected to transient middle cerebral artery occlusion (MCAO) followed by reperfusion. The rats were injected with Rd (1, 2.5, and 5 mg·kg(-1)·d(-1), ip) from d 1 to d 3 after MCAO, and with BrdU (50 mg·kg(-1)·d(-1), ip) from d 3 to d 6, then sacrificed on 7 d. The infarct size and neurological scores were assessed. Neurogenesis in the brains was detected by BrdU, DCX, Nestin, and GFAP immunohistochemistry staining. PC12 cells subjected to OGD/reperfusion were used as an in vitro model of brain ischemia. VEGF and BDNF levels were assessed with ELISA, and Akt and ERK phosphorylation was measured using Western blotting. Rd administration dose-dependently decreased the infarct size and neurological scores in the rats with IRI. The high dose of Rd 5 (mg·kg(-1)·d(-1)) significantly increased Akt phosphorylation in ipsilateral hemisphere, and markedly increased the number of BrdU/DCX and Nestin/GFAP double-positive cells in ischemic area, which was partially blocked by co-administration of the PI3 kinase inhibitor LY294002. Treatment with Rd (25, 50, and 100 μmol/L) during reperfusion significantly increased the expression of VEGF and BDNF in PC12 cells with IRI. Furthermore, treatment with Rd dose-dependently increased the phosphorylation of Akt and ERK, and significantly decreased PC12 cell apoptosis, which were blocked by co-application of LY294002.
    CONCLUSIONS:
    Rd not only attenuates ischemia/reperfusion injury in rat brain, but also promotes neurogenesis via increasing VEGF and BDNF expression and activating the PI3K/Akt and ERK1/2 pathways.
    Expert Rev Neurother. 2013 Jun;13(6):603-13.
    Ginsenoside Rd for acute ischemic stroke: translating from bench to bedside.[Pubmed: 23738998]
    Numerous studies have identified pathophysiological mechanisms of acute ischemic stroke and have provided proof-of-principle evidence that strategies designed to impede the ischemic cascade, namely neuroprotection, can protect the ischemic brain. However, the translation of these therapeutic agents to the clinic has not been successful. Ginsenoside Rd, a dammarane-type steroid glycoside extracted from ginseng plants, has exhibited an encouraging neuroprotective efficacy in both laboratory and clinical studies. This article attempts to provide a synopsis of the physiochemical profile, pharmacokinetics, pharmacodynamics, clinical efficacy, safety and putative therapeutic mechanisms of Rd. Finally, the authors discuss the validity of Rd as a neuroprotective agent for acute ischemic stroke.
    Vaccine. 2007 Jan 2;25(1):161-9.
    Ginsenoside Rd elicits Th1 and Th2 immune responses to ovalbumin in mice.[Pubmed: 16950547]
    Ginsenoside Rd (Rd), a saponin isolated from the roots of panax notoginseng, was evaluated for inducing Th1 or Th2 immune responses in mice against ovalbumin (OVA).
    METHODS AND RESULTS:
    ICR mice were immunized subcutaneously with OVA 100 microg alone or with OVA 100 microg dissolved in saline containing alum (200 microg), or Rd (10, 25 or 50 microg) on days 1 and 15. Two weeks later (day 28), concanavalin A (Con A)-, lipopolysaccharide (LPS)- and OVA-stimulated splenocyte proliferation was determined using MTT assay, and OVA-specific antibody titers and levels of cytokines in serum were measured by ELISA and microparticle-based flow cytometric immunoassay, as well as peripheral blood T-lymphocyte subsets analyzed using flow cytometer. Rd significantly enhanced the Con A-, LPS-, and OVA-induced splenocyte proliferation in the OVA-immunized mice. OVA-specific IgG, IgG1, and IgG2b antibody titers in serum were significantly enhanced by Rd compared with OVA control group. Meanwhile, Rd also significantly promoted the production of the Th1 and Th2 cytokines in OVA-immunized mice. Further, the effects of Rd on expression of cytokine mRNA in Con A-stimulated mice splenocytes were evaluated by RT-PCR analysis. Rd significantly enhanced the interleukin-2 (IL-2), interferon-gamma (IFN-gamma), IL-4, and IL-10 mRNA expression in mice splenocyte induced by Con A.
    CONCLUSIONS:
    These results suggested that Rd had immunological adjuvant activity, and elicited a Th1 and Th2 immune response by regulating production and gene expression of Th1 cytokines and Th2 cytokines.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 1.0557 mL 5.2787 mL 10.5574 mL 21.1149 mL 26.3936 mL
    5 mM 0.2111 mL 1.0557 mL 2.1115 mL 4.223 mL 5.2787 mL
    10 mM 0.1056 mL 0.5279 mL 1.0557 mL 2.1115 mL 2.6394 mL
    50 mM 0.0211 mL 0.1056 mL 0.2111 mL 0.4223 mL 0.5279 mL
    100 mM 0.0106 mL 0.0528 mL 0.1056 mL 0.2111 mL 0.2639 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    三七皂苷R4; Notoginsenoside R4 CFN91142 87741-77-3 C59H100O27 = 1241.4 5mg QQ客服:2159513211
    人参皂苷Ra2; Ginsenoside Ra2 CFN93293 83459-42-1 C58H98O26 = 1211.39 5mg QQ客服:3257982914
    三七皂苷Fe; Notoginsenoside Fe CFN93282 88105-29-7 C47H80O17 = 917.12 20mg QQ客服:3257982914
    人参皂苷Rc; Ginsenoside Rc CFN99973 11021-14-0 C53H90O22 = 1079.27 20mg QQ客服:215959384
    人参皂苷F1; Ginsenoside F1 CFN99754 53963-43-2 C36H62O9 = 638.88 20mg QQ客服:1413575084
    3-乙酰人参皂苷F1; 3-Acetyl-ginsenoside F1 CFN95238 1881225-08-6 C38H64O10 = 680.9 5mg QQ客服:1457312923
    人参皂苷F3; Ginsenoside F3 CFN99978 62025-50-7 C41H70O13 = 770.99 20mg QQ客服:215959384
    人参皂苷F5; Ginsenoside F5 CFN95034 189513-26-6 C41H70O13 = 771.0 20mg QQ客服:1413575084
    人参皂苷Rg1; Ginsenoside Rg1 CFN99967 22427-39-0 C42H72O14 = 801.01 20mg QQ客服:1413575084
    三七皂苷R1; Notoginsenoside R1 CFN99999 80418-24-2 C47H80O18 = 933.13 20mg QQ客服:2056216494

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ: 1413575084
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产